ETCK yields 666666.67% · ABBV yields 3.06%● Live data
📍 ETCK pulled ahead of the other in Year 1
Combined, ETCK + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ETCK + ABBV for your $10,000?
EnerTeck Corporation, through its subsidiary, EnerTeck Chemical Corp., manufactures, markets, and sells fuel borne catalytic engine treatment products for diesel engines in the United States and internationally. The company offers EnerBurn that functions as an engine treatment application by removing carbon deposits from the combustion surfaces of the engine and reducing further carbon deposit buildup to fleet and vessel operators. It also provides volumetric proportioning injection equipment, which is used to deliver proper dosage ratios of EnerBurn to the diesel fuel. The company's products are primarily used in on-road vehicles, locomotives, and diesel marine engines. Its principal target markets comprise trucking, heavy construction, maritime shipping, railroad, and mining industries, as well as federal, state, and international government applications. The company was formerly known as Gold Bond Resources, Inc. and changed its name to EnerTeck Corporation in November 2003. EnerTeck Corporation was incorporated in 1935 and is based in Stafford, Texas.
Full ETCK Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.